Form 4 for BVS Bioventus Inc.
Accepted 2026-03-24 00:00:00 ET · period of report 2026-03-20 · accession 0001914936-26-000007 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-03-24 | 2026-03-20 | BVS | Singleton Mark Leonard | SVP, CFO | M - OptEx | $0.00 | +18.6K | 178.1K | +12% | $0 |
| D | 2026-03-24 | 2026-03-20 | BVS | Singleton Mark Leonard | SVP, CFO | F - Tax | $8.64 | -8,091 | 170.0K | -5% | -$69.9K |
| D | 2026-03-24 | 2026-03-20 | BVS | Singleton Mark Leonard | SVP, CFO | M - OptEx | $0.00 | -18.6K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2026-03-20 | M | A | 18,625 | $0.00 | 178,072 | D | — | — | |
| 2 | Common | Class A Common Stock | 2026-03-20 | F | D | 8,091 | $8.64 | 169,981 | D | — | — | |
| 3 | Derivative | Restricted Stock Units | 2026-03-20 | M | D | 18,625 | $0.00 | 0 | D | — · — to — | 18,625 Class A Common Stock | (F1) Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. (F2) The original grant of 74,500 RSUs vested in four approximately equal annual installments that began on March 21, 2023. |